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cis-Pt I2(NH3)2: a Reappraisal 
Tiziano Marzo,a Serena Pillozzi,b Ondrej Hrabina,c Jana Kasparkova,d Viktor Brabec,d 
Annarosa Arcangeli,b Gianluca Bartoli,b Mirko Severi,e Alessandro Lunghi,e Federico 
Totti,e  Chiara Gabbiani,f Adóracion G. Quirogag and Luigi Messori*a   
The investigation of cis-PtI2(NH3)2, the diiodido analogue of cisplatin (cisPtI2 hereafter), has 
been unjustly overlooked so far mainly because of old claims of pharmacological inactivity. 
Some recent -but still fragmentary- findings prompted us to reconsider more systematically the 
chemical and biological profile of cisPtI2 in comparison to cisplatin. Its solution behaviour, 
interactions with DNA and cytotoxic properties versus selected cancer cell lines were thus 
extensively analysed through a variety of biophysical and computational methods. Notably, we 
found that cisPtI2 is highly cytotoxic in vitro toward a few solid tumour cell lines and that its 
DNA platination pattern closely reproduces that of cisplatin; cisPtI2 is also shown to overcome 
completely resistance to cisplatin in a platinum resistant cancer cell line. The differences in the 
biological actions of these two Pt complexes are most likely related to slight but meaningful 
differences in their solution behaviour and reactivity. Overall, a very encouraging and 
unexpected pharmacological profile emerges for cisPtI2 with relevant implications both in 
terms of mechanistic knowledge and of prospective clinical application. An ab initio DFT 
study is also included to support the interpretation of the solution behaviour of cisPtI2 under 
physiological and slightly acidic pH conditions.  
 
Introduction 
 Cisplatin is a leading compound in the field of anticancer 
drugs. Together with its two main parent Pt drugs, i.e. 
carboplatin and oxaliplatin, it is currently used in about half of 
chemotherapeutic protocols for cancer treatment.1-3 Since the 
discovery of its outstanding anticancer properties during the 
60’s and subsequent clinical approval by FDA, in 1978, 
cisplatin has been the subject of hundreds of studies to describe 
and understand its peculiar chemical behaviour, and elucidate 
the mechanisms of its biological and pharmacological effects.4-6   
 A quite wide consensus now exists concerning the likely 
mode of action of anticancer Pt drugs that mainly relies on 
direct DNA damage, impairment of fundamental DNA 
functions and consequent triggering of apoptosis;1,2 yet, several 
issues and details remain unexplored and/or unanswered, so 
that other mechanistic hypotheses -even DNA unrelated- have 
been advanced.7,8  
 The great clinical success of cisplatin has inspired an 
intense search for platinum analogues with hopefully improved 
biological and pharmacological properties;9-13 however, the 
outcomes of these research activities turned out to be quite 
modest and disappointing, both in terms of identification of 
new clinically effective Pt agents and of discovery of 
innovative modes of action. 
 
 
 
 
 
 
 
 
Fig. 1 Structure of cisplatin and its diiodido analogue  
 
 Despite the huge research efforts made on platinum 
analogues over the last three decades, we were surprised in 
learning that only rare studies were carried out on cisPtI2, the 
strict iodo analogue of cisplatin. This is probably the 
consequence of an initial negative assessment by Hoeschele and 
Cleare,14a who reported that cisPtI2 is nearly inactive in animal 
models of sarcoma 180 while warning about its extremely low 
aqueous solubility and the difficulty in determining the toxic 
dose. Accordingly, even the cytotoxicity profile of cisPtI2  
against the 60 cancer cell lines panel of NCI has never been 
reported. 
 However, more recently, a few studies started reconsidering 
iodido platinum complexes as possible anticancer drug 
candidates. For instance, Kratochwil et al., described some 
diamino diiodido platinum(II) complexes manifesting an 
appreciable cytotoxicity in vitro.15 In the last few years, we 
discovered that some mixed diamino diiodido Pt complexes 
  
exhibit appreciable cytotoxic properties in vitro.16-18 Moreover, 
for some of these Pt complexes, in spite of their lower reactivity 
with DNA as compared to cisplatin, an unconventional 
reactivity toward the model protein cytochrome c was 
disclosed, unexpectedly characterized by the loss of the amino 
ligands and retention of iodido ligands.16,17 Furthermore, in a 
paper published in 2013, we structurally described the reaction 
of cisPtI2 with lysozyme, confirming the peculiar and different 
interaction mode toward this model protein in comparison to 
cisplatin.19 Yet, no study has re-evaluated so far the biological 
profile of cisPtI2. Altogether, these arguments led us to 
reconsider, in a more systematic way, some key chemical and 
biological aspects of cisPtI2 with respect to cisplatin.  
 Specifically, we have focused our attention on the four 
following issues : i) the activation process of cisPtI2 in aqueous 
solutions both at physiological and slightly acidic pH; ii) a 
computational rationalization of the spectral results;  iii) the 
investigation of the direct reaction of cisPtI2 with DNA; iv) the 
cellular effects of cisPtI2 in a small panel of cancer cell lines. 
Some notable results have emerged from these studies that are 
comprehensively analysed and discussed here in direct 
comparison to cisplatin, with relevant mechanistic and medical 
implications. 
 
Experimental 
Chemistry of cis-PtI2(NH3)2 
Synthesis of cis-PtI2(NH3)2 and UV-Vis analysis. cisPtI2 was 
synthesized according to published procedures,  using (1:4) 
Pt:KI in order to avoid further purifications.17,20 The purity of 
the product was checked by elemental analysis of C, N and H 
[Calculated C: 0%, H: 1,26%, N: 5,84%, Experimental: C: 0%, 
H: 1,12%, N: 5,71%.], and as described in ref. 14b. The correct 
cis geometry was assessed by comparison with its trans 
analogue as describe in the literature.14 Solution behaviour of 
cisPtI2 was assessed through spectrophotometric studies 
performed with a Varian Cary 50 Bio UV-Vis 
spectrophotometer in buffered solutions without use of DMSO 
and in absence of NaCl. A solution of complex (10-4 M) was 
prepared in 50 mM phosphate buffer (with or without presence 
of KI) at pH=7.4 or in 20 mM ammonium acetate buffer at 
pH=4.5 and absorbance monitored in the range between 200 
and 800 nm of wave length for 72 h at 25° C.   
 
Density Functional Theory simulations ORCA package has 
been used throughout the calculations.21 Hybrid PBE0 
functional22 and Aldrich TZVP gaussian basis sets with scalar 
relativistic (ZORA) corrections23 were used for both geometry 
optimizations and spectra simulations. Excited states have been 
computed within the TDDFT approach24 and only the first 
twenty transitions have been computed using 200 expansion 
vectors in the iterative solution of the CI equations. D3 
Grimme's dispersion corrections25 have also been included. 
Solvent effects have been take into account within the COSMO 
model26,27 with an  value of 80.4. Highly accurate integration 
grids (Grid 5 in the ORCA notation) without pruning of the 
inner angular part of the wave function and “TightSCF” 
convergence criteria has been used throughout all the 
calculations 
 
LogP determination. The octanol-water partition coefficients 
for cisplatin and cisPtI2 were determined by modification of 
reported shake-flask method.28 Water (50 mL, distilled after 
milli-Q purification) and n-octanol (50 mL) were shaken 
together for 72 h to allow saturation of both phases. Solution of 
the complexes were prepared in the water phase (3 x 10-3 M) 
and an equal volume of octanol was added. Biphasic solutions 
were mixed for ten minutes and then centrifuged for five 
minutes at 6000 rpm to allow separation. Concentration in both 
phases was determined by UV-VIS. Reported logP is defined as 
log [complex]oct/[complex]wat. Final values were reported as 
mean of three determinations. 
 
Uptake experiment: comparison between cisplatin and cis-
PtI2(NH3)2 HCT116 cell line. The determination of platinum 
concentration in the cellular pellets as well as in the 
corresponding supernatant samples was performed in triplicate 
by a Varian  720-ES Inductively Coupled Plasma Atomic 
Emission Spectrometer (ICP-AES) equipped with a CETAC 
U5000 AT+ ultrasonic nebulizer, in order to increase the 
method sensitivity. Before the analysis, samples were weighted 
in PE vials and digested in a thermo-reactor at 80 °C for 24 h 
with 2 mL of aqua regia (HCl suprapure grade and HNO3 
suprapure grade in 3:1 ratio) and 0.2 mL of H2O2 suprapure 
grade. After digestion, the samples were diluted to about 5 mL 
with ultrapure water (≤18 MΩ) and accurately weighed; 5.0 mL 
of each sample were spiked with 1 ppm of Ge used as an 
internal standard, and analysed. Calibration standards were 
prepared by gravimetric serial dilution from a commercial 
standard solution of Pt at 1000 mg L−1. The wavelength used 
for Pt determination was 214.424 nm whereas for Ge was used 
the line at 209.426 nm. The operating conditions were 
optimized to obtain maximum signal intensity, and between 
each sample, a rinse solution constituted by HCl suprapure 
grade and HNO3 suprapure grade in 3:1 ratio was used in order 
to avoid any “memory effect”. 
Cellular studies 
Cell cultures. PANC-1, HCT116-S, HCT116-R, IGROV-1, 
A549 and HT29  cell lines were cultured in RPMI 1640 
(Euroclone; Milan, Italy) with 10% Fetal Bovine Serum (FBS) 
(Euroclone Defined; Euroclone; Milan, Italy). HCT116 cells 
were kindly provided by Dr. R. Falcioni (Regina Elena Cancer 
Insitute, Roma). We cultured at 37 °C in a humidified 
atmosphere in 5% CO2 in air. 
  
Pharmacology experiments. Cells were  seeded in a 96-well 
flat-bottomed plate (Corning-Costar, Corning, NY, USA) at a 
cell density of 1 x 104 cells per well in RPMI complete 
medium. Drugs were used, after solubilisation in water, without 
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use of DMSO, at the final concentrations indicated in the 
figures and in the legends to the figures. After 24 h, viable cells 
(determined by Trypan blue exclusion) were counted in 
triplicate using a haemocytometer. Each experimental point 
represents the mean of four samples carried out in three 
separate experiments.  
 
Trypan blue assay. Cells viability was assessed by the Trypan 
blue exclusion assay. In brief, 10 µL of 0.4% trypan blue 
solution was added to 10 µL cell suspensions in culture 
medium.      
 The suspension was gently mixed and transferred to a 
haemocytometer. Viable and dead cells were identified and 
counted under a light microscope. Blue cells failing to exclude 
dyes were considered nonviable, and transparent cells were 
considered  viable. The percentage of viable cells was 
calculated on the basis of the total number of cells (viable plus 
non viable). The IC50 value (i.e., the dose that caused apoptosis 
of 50% of cells) was calculated by fitting the data points (after 
24 h of incubation) with a sigmoidal curve using Calcusyn 
software.  
 
Cell cycle analysis. The effect of cisplatin and cisPtI2 on cell cycle 
distribution was assessed by flow cytometry after staining cells with 
propidium iodide (PI). Briefly, the cells (5 x 105 cells mL-1) were 
analyzed prior and after treatment with IC50s of both drugs (20.98 
µM and 7.3 µM) for 24 h. The cells were harvested, washed with 
PBS and resuspended in 300 μL 1X Propidium Iodide staining 
solution and incubate at 4 °C in the dark for 20 minutes. DNA 
content of the cells was measured by BD FACSCanto Flow 
Cytometer and the population of each phase was determined using 
ModFit LT 3.0 analysis software (Verity Software House, Topsham, 
ME USA). 
DNA binding studies. 
Reaction of cisPtI2 with DNA, its putative main target, was 
analysed in direct comparison with cisplatin through a robust 
experimental approach including quantification of Pt binding to 
DNA, DNA interstrand cross-linking analysis, DNA adducts 
characterization by ethidium bromide fluorescence, DNA 
unwinding and thermal stability analyses.  
Quantitative evaluation of binding of cis-PtI2(NH3)2 and 
cisplatin to mammalian DNA in a cell-free medium. 
Solutions of double-helical calf thymus (CT) DNA (42% G + 
C, mean molecular mass approximately 2 x 107) at a 
concentration of 0.032 mg mL-1 (1 x 10-4 M related to the 
phosphorus content) were incubated with cisPtI2 (8 μM) or 
cisplatin (8 μM) at a value of rf = 0.08 in 0.1 mM KI or KCl, 
respectively, at 37 °C (rf is defined as the molar ratio of free 
platinum complex to nucleotide phosphates at the onset of 
incubation with DNA). Two different stock solutions of cisPtI2 
(0.1 mM) or cisplatin (0.1 mM) were prepared. One contained 
the PtII complex incubated for 7 days in unbuffered KI or KCl, 
respectively (0.01 M, pH 6) at 37 °C in the dark, whereas the 
other contained PtII complexes incubated for 7 days in double 
distilled water at 37 °C in the dark. Fifty microliters of the PtII 
complex aged in KI/KCl (0.01 M) or in water were quickly 
mixed with 4950 μL of DNA dissolved in NaClO4 (10 mM), 
and the reaction mixture was kept at 37 °C. In the experiments 
in which the PtII complex aged in water was used, the final 
reaction mixture was still supplemented at the onset of the 
reaction with KI or KCl so that the resulting concentration of 
KI or KCl in the reaction mixtures was always 0.1 mM. At 
various time intervals, an aliquot of the reaction mixture was 
withdrawn and assayed by differential pulse polarography 
(DPP) for platinum not bound to DNA.29 
Platination reactions.  If not stated otherwise, CT or plasmid 
DNAs were incubated with the platinum complex in 10 mM 
NaClO4 at 37 °C in the dark. After 24 h, the samples were 
exhaustively dialyzed against the medium required for 
subsequent biochemical or biophysical analysis. An aliquot of 
these samples was used to determine the value of rb (rb is 
defined as the number of molecules of the platinum complex 
bound per nucleotide residue) by flameless atomic absorption 
spectrophotometry (FAAS) or by differential pulse 
polarography (DPP).29 
Unwinding of negatively supercoiled DNA. Unwinding of 
closed circular supercoiled pSP73KB plasmid DNA (2455 bp) 
was assayed by an agarose gel mobility shift assay.30 The 
unwinding angle Φ, induced per platinum–DNA adduct was 
calculated upon the determination of the rb value at which the 
complete transformation of the supercoiled to the relaxed form 
of the plasmid was attained. Samples of pSP73KB plasmid 
were incubated with platinum compounds at 37 °C in the dark 
for 24 h. The samples were subsequently subjected to 
electrophoresis on 1% agarose gels running at 25°C with 
tris(hydroxymethyl) aminomethane (Tris)–acetate–EDTA 
buffer. The gels were then stained with EtBr, followed by 
photography with a transilluminator. 
DNA melting. The melting curves of CT DNAs were recorded 
by measuring the absorbance at 260 nm. The melting curves 
were recorded in a medium containing 10 mM or 0.1 M Na+ 
with 1 mM Tris–HCl/0.1 mM Na2H2EDTA, pH 7.4. The value  
  
of the melting temperature (tm) was determined as the 
temperature corresponding to a maximum on the first derivative 
profile of the melting curves.  
Interstrand DNA cross-linking in a cell-free medium. cisPtI2 
or cisplatin were incubated for 24 h with 0.5 µg of a linear 
2686-bp fragment of pUC19 plasmid linearized by EcoRI. The 
linear fragment was first 3´-end-labeled by means of the 
Klenow fragment of DNA polymerase I in the presence of [α-
32P]dATP. The platinated samples were analyzed for DNA 
interstrand crosslinks by previously published procedures.31,32  
The number of interstrand cross-links was analyzed by 
electrophoresis under denaturing conditions on alkaline agarose 
gel (1%). After the electrophoresis had been completed, the 
intensities of the bands corresponding to single strands of DNA 
and interstrand cross-linked duplex were quantified. The 
frequency of interstrand cross-links was calculated as ICL/Pt 
(%) = XL/5372rb (the DNA fragment contained 5372 
nucleotide residues), where ICL/Pt (%) is the number of 
interstrand cross-links per adduct multiplied by 100, and XL is 
the number of interstrand cross-links per molecule of the 
linearized DNA duplex, which was calculated assuming a 
Poisson distribution of the interstrand crosslinks as XL = -ln A, 
where A is the fraction of molecules running as a band 
corresponding to the non-cross-linked DNA. 
Characterization of DNA adducts by EtBr fluorescence. 
These measurements were performed on a Varian Cary 
fluorescence spectrophotometer using a 1 cm quartz cell.  
 Fluorescence measurements were performed at an excitation 
wavelength of 546 nm, and the emitted fluorescence was 
analyzed at 590 nm. The fluorescence intensity was measured 
at 25 °C in NaCl (0.4 M) to avoid secondary binding of EtBr to 
DNA.26 The concentrations were 0.01 mg mL−1 for DNA and 
0.04 mg mL-1 for EtBr, which corresponded to the saturation of 
all intercalation sites of EtBr in DNA.33 
 
Other physical methods: Absorption spectra were measured 
with a Beckman 7400 DU spectrophotometer equipped with a 
thermoelectrically controlled cell holder. The FAAS 
measurements were conducted with a Varian AA240Z Zeeman 
atomic absorption spectrometer equipped with a GTA 120 
graphite tube atomizer. The gels were visualized with a 
FUJIFILM BAS 2500 bioimaging analyzer, and the 
radioactivity associated with the bands was quantified with 
AIDA Image Analyzer. DPP measurements were performed 
using an EG&G PARC Electrochemical Analyzer, model 384B. 
 
Results  
Solution Chemistry of cis-Pt I2(NH3)2:  logP determination and 
activation profile in aqueous buffers 
  
We first investigated some unexplored chemical features of cisPtI2; 
in particular we determined its logP value and analysed its 
solution behaviour under various conditions and the inherent 
metal complex activation processes. 
 The logP of cisPtI2 was measured according to the method 
reported in the experimental section; a value of -0.13 was 
determined versus a value of -2.4 previously determined for 
cisplatin and here again confirmed. This result implies that 
cisPtI2, in its intact form, is far more lipophylic than cisplatin: 
this might have some appreciable impact on its cellular uptake 
(see later). 
 Then, the solution behaviour of cisPtI2 was studied 
spectrophotometrically under physiological-like or slightly 
acidic pH conditions. Remarkably, freshly prepared aqueous 
solutions of cisPtI2, at pH=7.4, manifest two intense bands in 
the UV-visible region, located at 290 and 350 nm, respectively, 
that allow the direct and continuous monitoring of the solution 
behaviour of this platinum complex (Figure 2). 
Fig. 2 time dependent UV-Vis analysis of complex cis-
PtI2(NH3)2 10-4 M in 50 mM phosphate buffer (pH=7.4) 
followed for 72 h. 
 
 Some important spectral changes are slowly detected 
consisting in the progressive and regular decrease of the two 
main bands and in the appearance of a new band, of lower 
intensity, around 280 nm. The observed spectral changes are 
tentatively traceable to the progressive release of the two iodido 
ligands and to their replacement by water molecules according 
to a moderately biphasic kinetics. This would mean that the 
aquation process of cisPtI2 reproduces quite closely that of 
cisplatin, involving the progressive detachment of the two 
halide ligands while both ammonia ligands are kept as 
confirmed by some further experiments. In particular, addition 
of KI at increasing concentrations completely abolished and 
even reverted the above described spectral changes (see SI) 
strongly supporting the proposed interpretation. In any case, the 
rate of the aquation process for cisPtI2 is appreciably  slower 
than for cisplatin (by at least a factor 2) possibly because of the 
greater strength of the Pt-I bond and/or greater inertness related 
to the increased "soft” character of iodide over chloride (more 
details for hydrolysis process and UV-Vis analysis are given in 
the SI).   
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 To gain further insight into the activation processes of 
cisPtI2, we also analysed its spectral behaviour under slightly 
acidic conditions. Indeed, a mildly acidic environment is 
thought to destabilise the ammonia ligands and thus favour 
ammonia release over iodide release. Accordingly, cisPtI2 was 
dissolved in an acetate buffer, at pH 4.5, and its spectral 
changes monitored over 72 hours. The resulting spectral  profile 
is shown in Figure 3: it is apparent that the overall spectral 
profile is profoundly different from that recorded at 
physiological pH. In particular, a new and quite intense visible 
band is clearly detected around 410 nm, at 72 hours, whose 
assignment is discussed later. 
Fig. 3 UV-Vis spectral  changes of complex cis-Pt I2(NH3)2 10-
4 M in 50mM Acetate buffer (pH=4.5) followed for 72h. Gray 
line t=0 h, red line t=72 h. 
 
Computational studies, simulation of UV-Vis spectra 
 
 To interpret the reported spectral profiles at two distinct pH 
values, we performed UV-Vis spectra simulations of 5 species: 
the native cisPtI2, two products of the Iodido aquation 
mechanism i.e. [cis-PtI(H2O)(NH3)2]+ (1), [cis-
Pt(H2O)2(NH3)2]2+ (2) and two products related to ammonia 
aquation mechanism i.e. [cis-PtI2(NH3)(H2O)] (3), [cis-
PtI2(H2O)2] (4). 
 The computed spectrum of cisPtI2 (cfr. red line in Figure 
4a) is in very good agreement with the experimental one 
reported in Figure 2. The calculated spectra for the mono- and 
di-Iodido hydrolysis species, i.e. (1) and (2), reproduce closely 
the experimental spectral evolution shown in Figure 2, offering  
strong support to the iodide release mechanism. 
Simulated bands assignments were done through transition 
density plots reported in Figure 4b. It is possible to observe 
that, for cisPtI2, band A is a LMCT transition, I,O(px,y) →Pt(dx2-
y2), while band B is a platinum d-d transition, Pt(dxy) → Pt(dx2-
y
2). Notably,  band A changes from a LMCT to a platinum d-d 
character passing from cisPtI2 to species (1) and (2). For (1), 
both bands have a Pt(dxy) → Pt(dx2-y2) character. For (2) we 
observed that (B) band observed for the cisPtI2 undergoes  a 
blue shift until it turns into band (A).  
 Band B conserved the Pt(dxy) → Pt(dx2-y2) character 
observed for (2). Such behavior is in agreement with expected d 
orbitals shifts due to substitution of a strong basic  donor as 
iodide with one water molecule. 
 
a) 
 
b) 
 
Fig. 4 (a) Evolution of UV-Vis spectral features for the Iodide 
hydrolysis mechanism. (b) Evolution of the electronic transition’s 
nature of A and B bands during the iodido aquation mechanism (cis-
PtI2(NH3)2 top, [cis-PtI(H2O)(NH3)2]+ middle and [cis-
Pt(H2O)2(NH3)2]2+ bottom): for each transition red densities 
correspond to arrival orbitals and blue densities correspond to 
starting molecular orbitals. Platinum ions are coloured in silver, 
nitrogen in blue, oxygen in red, iodide in violet and hydrogen in 
white. 
  
  To verify the correctness of the supposed iodide hydrolysis 
mechanism for physiological-like pH conditions, we have 
calculated the UV-Vis spectra (see Figure 5a) also for the 
species involved in the concurrent amino hydrolysis 
mechanism, i.e. (3) and (4).  In this case, the two cisPtI2 bands 
undergo a significant red shift keeping their shape and relative 
intensities practically unchanged. Interestingly, the same 
behavior is experimentally observed for acidic conditions (cfr. 
Fig. 3), where, indeed, the release of the ammonia ligands is 
expected. Furthermore, since dimeric species of the type 
[Pt(amine)I2]2, that are active on selected cancer cell lines, were 
reported to be synthesised in acidic conditions34, additional ESI 
MS experiments were carried out at pH=4.5. Formation of 
dimers in solution under the latter conditions is confirmed by 
the presence of few weak peaks assignable to these species  
(see SI).   
 
a) 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 (a) Evolution of UV-Vis spectral features for the 
ammonia hydrolysis mechanism. (b) Evolution of the electronic 
transition’s nature of A and B bands during the ammonia 
aquation mechanism (cis-PtI2(NH3)2 top, [cis-PtI2(NH3)(H2O)] 
middle and [cis-PtI2(H2O)2] bottom): for each transition red 
densities correspond to arrival orbitals and blue densities 
correspond to starting molecular orbitals. Colour code as in Fig. 
4. 
 
The difference transitions MOs analysis performed for this 
second group of molecules is shown in Figure 5b; it is observed 
that the nature of the main spectral transitions is retained for all 
species involved. In this case, only the shift of valence 
molecular orbitals has been observed due to the similar orbital 
contributions of ammonia and water molecules. Therefore 
bands (A) and (B) can be described as I,O(px,y) → Pt(dx2-y2), 
Pt(dxy) → Pt(dx2-y2) transitions, respectively. 
DNA binding properties of cis-PtI2(NH3)2  
 To determine the nature of the DNA interactions of cisPtI2, 
the DNA binding properties of this complex were examined 
through a variety of methods and compared with those of 
cisplatin. First, we aimed at quantifying the binding of cisPtI2 
to mammalian (CT) double-helical DNA in a cell free medium. 
 The amount of platinum bound to DNA increased with time 
and the times at which the binding reached 50% (t50%) are 
summarized in Table 1.  
 
Compound t50% (min)a 
cis-PtI2(NH3)2 aged in H2O 105 ± 11 
cisplatin aged in H2O   64 ± 5 
cis-PtI2(NH3)2 aged in 10 mM KI 390 ± 24 
cisplatin aged in 10 mM KCl 136 ± 19 
 
a The time at which the binding reached 50%. Values shown in 
the table are the means ± SEM of three separate experiments. 
 
Table 1  Binding of cis-PtI2(NH3)2 and cisplatin to calf thymus 
DNA. 
 
 Importantly, after 24 h, cisPtI2 and cisplatin aged in water 
or in 10 mM KI/KCl were quantitatively bound. As expected, 
the PtII complexes preincubated in water reacted with DNA 
significantly more rapidly than those preincubated in KI/KCl 
(10 mM), but the rate of the reaction of cisplatin was 
considerably higher than that of cisPtI2. 
 The lower rate of the reaction of cisPtI2 with double-helical 
DNA in comparison with that of cisplatin can be interpreted to 
mean35 that the rate of the aquation of the leaving ligands in 
cisPtI2 is significantly lower than that in cisplatin. Since 
interstrand and intrastrand cross-links formation are believed to 
be responsible for anticancer activity of bifunctional platinum 
compounds, we have quantitated the interstrand cross-linking 
efficiency of cisPtI2 in the linear pUC19 DNA (linearized with 
EcoRI restriction enzyme). Results point out that interstrand 
cross-linking efficiency of cisPtI2 (5 ± 2%) was similar to that 
of cisplatin (6 %) (see SI for further details).32 
 Afterward, to gain more information about the adducts 
formed in the reaction of cisPtI2 with DNA, in comparison with 
those produced by cisplatin, experiments with the fluorescent 
probe ethidium bromide have been carried out. Double helical 
DNA was first modified by the PtII complex (cisPtI2 or 
cisplatin) for 24 h. The levels of the modification corresponded 
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to the values of rb in the range between 0 and 0.1. Modification 
of DNA by both platinum complexes resulted in a decrease of 
EtBr fluorescence (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Ethidium bromide fluorescence. Dependences of the 
EtBr fluorescence on rb for CT DNA modified by platinum 
complexes in 10 mM NaClO4 at 37 °C for 24 h. Open symbols, 
cis-PtI2(NH3)2; closed symbols, cisplatin. 
 
 The formation of adducts of cisPtI2 resulted in a progressive 
decrease of EtBr fluorescence intensity, which was similar to 
that of cisplatin. This result suggests that the conformational 
distortion induced in DNA by the adducts of cisPtI2 is 
delocalized and extends over the same number of base pairs 
around the platination sites as in the case of the adducts of 
cisplatin. 
 Even DNA unwinding experiment suggests the same mode 
of metalation between cisplatin and its iodide analogue (see SI 
for further experimental details). Using this approach, we 
determined the DNA unwinding angles to be in the range 11 ± 
2° for cisPtI2, which is very similar to that found for cisplatin 
(13°).30 Finally thermal stability experiment of DNA has been 
carried out. 
  CT DNA was modified by cisPtI2 to the value of rb = 0.03–
0.09. After the modification, the salt concentration was further 
adjusted by addition of NaCl to 0.1 M, and the samples were 
further supplemented by Tris-HCl (1 mM) and EDTA (0.1 
mM). Thus, the melting curves for DNA modified by the 
platinum compounds were measured at a relatively high salt 
concentration (Table 2). We found that the effect of DNA 
platination by cisPtI2 on the melting temperature of DNA (tm) is 
similar to that observed for the modifications by cisplatin.  
 Three major factors have been invoked to account for the 
thermal stability of DNA modified by PtII complexes capable of 
DNA cross-linking and the observed change in melting 
temperature of DNA as a consequence of its platination reflects 
the relative proportion and contribution of these three factors.36  
 These three factors are (i) a destabilizing effect of 
conformational distortions due to the formation of cross-links 
induced in DNA by platinum coordination; (ii) stabilizing 
effects of DNA interstrand cross-links which prevent 
dissociation of DNA strands; (iii) the positive charge on the PtII 
centers (introduction of a positive charge into the DNA 
molecule, e.g. by binding of positively charged ligands such as 
PtII moieties of platinum compounds, results in a stabilization of 
the DNA duplex by decreasing electrostatic repulsion of 
negative charges of phosphate groups located at the 
complementary strands). 
     
 rb = 0.03 rb = 0.06 rb = 0.09 
cis-PtI2(NH3)2 -1.9 ± 0.1 -5.0 ± 0.1 -7.9 ± 0.3 
cisplatin -2.1 ± 0.3 -5.2 ± 0.3 -8.3 ± 0.3 
 
a Δtm is defined as the difference between the tm values of 
platinated and unmodified DNAs. 
b The tm values were measured in the medium containing 
NaClO4 (0.1 M), Tris–HCl (1 mM, pH 7.4) and EDTA (0.1 
mM). 
c Values shown in this table are the means ± SEM of three 
separate experiments. 
 
Table 2  Δtm (°C) valuesa of CT DNA modified by cis-
PtI2(NH3)2 or cisplatinb,c. 
 
 Thus, it is reasonable to conclude that the decreases in tm 
are caused by destabilizing conformational distortions and that 
these destabilizing factors dominate over the interstrand cross-
links formed by both cis-platinum compounds and by positive 
charges on platinum moieties.  
 Owing to the fact that both cisPtI2 and cisplatin carry the 
same 2+ charge on platinum moiety and form approximately 
identical amount of interstrand cross-links (5 or 6%, 
respectively, vide supra), the values of tm yielded by the 
adducts of both complexes reflect mainly destabilizing effects 
of conformational distortions induced by the platinum-DNA 
adducts. Hence, the results of DNA melting experiments are 
consistent with the thesis that DNA adducts of cisPtI2 distort 
and destabilize double helix of DNA approximately in the same 
extent as DNA adducts of cisplatin. 
 From an overall inspection of the obtained results it is 
evident that cisPtI2 interacts with DNA through a mode of 
interaction that is very similar to that well documented for 
cisplatin. Apparently, the major difference consists of a 
somewhat slower kinetics of platinum association to DNA 
while the formed adducts are apparently the same.  
  
Cellular actions of cis-Pt I2(NH3)2 
 Afterward, the antiproliferative effects of cisPtI2 were 
evaluated in a representative panel of cancer cell lines 
according to the method described in the experimental section.  
 The cancer cell panel included the following lines: PANC-1 
(human pancreatic cancer), IGROV-1 (human ovarian cancer), 
A549 (human lung cancer), HT29 (human colon cancer), 
HCT116-S and HCT116-R (human colon cancer). These cells 
were exposed to increasing concentrations of the drugs in the 
range 0-200 μM; after 24 hours viable cells (determined by 
Trypan blue exclusion) were counted and the IC50 values 
determined. The measured IC50 values are reported in Table 3.    
  
cell line cisplatin cis-PtI2(NH3)2 
PANC-1 2.48±0.11 0.91±0.10 
IGROV-1 25.30±0.40 7.36±0.31 
A549 5.77±0.60 3.54±0.49 
HT29 16.39±1.10 11.69±1.40 
HCT116-S 7.65±0.63 13.42±0.49 
HCT116-R 21.96±1.11 4.15±0.23 
 
Table 3  IC50 values (µM) of cisplatin and its iodo analogue in 
a panel of cancer cell lines. 
 
 From data inspection it is evident that cisPtI2, in the four 
cisplatin sensitive cell lines, produces on the whole cytotoxic 
effects comparable and often greater than cisplatin. Extremely 
meaningful is the case of IGROV-1 where the cytotoxicity of 
cisPtI2 is far higher than cisplatin (IC50 =7.36 μM versus 25.30 
μM). Moreover, very remarkably, cisPtI2 is found to overcome 
completely resistance to cisplatin in the cisplatin-resistant 
HCT116-R line. These results are very relevant and unexpected 
if one considers that cisPtI2 is commonly reputed as inactive. 
 The effects of cisPtI2 on the cell cycle were also analysed in 
HCT116-R cells in comparison to cisplatin; an arrest in G2/M 
phase is clearly detected in both cases as well as a decrease of 
the S phase (Figure 7). 
 
 
 
 
 
 
a)                                                  b) 
 
Fig. 7 Cell cycle analysis in HCT116 treated with cisplatin (a) 
or cisPtI2 (b). 
 
 Analytical determinations were then carried out to measure 
intracellular Pt content  in HCT116-S and HCT116-R cells after 
exposure to equimolar concentrations of either cisplatin or  
cisPtI2. More precisely, cells were exposed to a 20 µM 
concentration of the Pt complexes for 3 h.  Results expressed as 
Pt content per cell in the various cases and as percentage of 
internalised Pt are reported in Table 4.  
 
Cell line Drug 
Platinum 
level 
Internalised Pt 
% 
HCT116-S cisplatin 2.53x10-8 µg 
0,98 
HCT116-S cis-
PtI2(NH3)2 
5.37x10-8 µg 
1,91 
HCT116-R cisplatin 1.46x10-8 µg 
0,50 
HCT116-R cis-
PtI2(NH3)2 
6.66x10-8 µg 
2,41 
 
Table 4 Platinum level (per cell) measured after exposure (3 
hours) of cell lines to 20 µM of cisplatin and cisPtI2.    
 
 From inspection of Table 4 it is evident that cisPtI2 
manifests a greater ability to enter both types of cells than 
cisplatin;  such difference is more evident in the Pt resistant cell 
line compared to the Pt sensitive one  (5 folds vs 2 folds). This 
is possibly linked to its greater lipophilic character and larger  
inertness.  
 Furthermore, in the resistant cell line (HCT116-R), we can 
pinpoint the correlation occurring between the above IC50 
values and Pt uptake in the sense that a greater cytotoxicity is 
associated to a greater Pt uptake -in terms of a five fold 
difference- proving the capability of cisPtI2 to overcome 
chemo-resistance.  
 
Discussion and Conclusions 
 The substantial lack of information concerning cisPtI2 
despite its striking similarity to cisplatin has inspired the 
present study; notably, some crucial aspects of its chemical and 
biological profile have been  eventually elucidated.   
 First, we have shown that cisPtI2 manifests a solution 
behaviour very similar to cisplatin when dissolved in an 
aqueous medium, at physiological pH; indeed, as seen for 
cisplatin, cisPtI2 undergoes activation through sequential slow 
release of its two iodido ligands that are replaced by water 
molecules. However, the process is appreciably slower than in 
the case of cisplatin. These statements are clearly supported 
both by experimental data (see SI) and computational analysis.  
The alternative hydrolysis path, where preferential release of 
NH3 ligands is observed, could  also be induced by changing 
the pH conditions. Even in this latter case the reaction route has 
been characterized by spectrophotometric analysis  and spectral 
simulations. The large differences observed between the 
spectral patterns associated to the two possible mechanisms are 
very consistent with our interpretation.  
 Then, the reactions of cisPtI2 with DNA were investigated 
in detail in direct comparison to cisplatin through a robust 
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experimental approach involving a variety of independent 
biophysical methods. Remarkably, we found that the pattern of 
DNA platination produced by cisPtI2 is highly reminiscent and 
nearly superimposable to that of cisplatin though the kinetics of 
the DNA metalation process is again appreciably slower. 
 Afterward, the cellular effects induced by cisPtI2 were 
explored in a small but representative panel of solid tumor cell 
lines; the panel included PANC-1 (human pancreatic cancer), 
IGROV-1 (ovarian cancer), A549 (lung cancer), HT29 (colon 
cancer), HCT116-S (colon cancer) and HCT116-R cells. Very 
remarkably, we observed that cisPtI2, in contrast to 
expectations and to the current opinion, is on the whole more 
cytotoxic than cisplatin in three out of four cisplatin sensitive 
cancer cells; on the other hand, cisPtI2 was found to overcome 
completely resistance to cisplatin in the cisplatin resistant 
HCT116-R cell line. This latter result implies that cisPtI2 is able 
to circumvent the molecular mechanisms that reduce sensitivity 
to cisplatin in the resistant line. On the other hand, it is unlikely 
that dimeric Pt species (see SI) play a major role in the 
observed cytotoxicity as the latter species are detected only at 
acidic pH and in very low amounts.   
 Analytical determinations were carried out to measure Pt 
uptake in the various cases: we found that cisplatin manifested 
a far lower ability to enter cells than cisPtI2. In addition, a 
pronounced reduction of Pt uptake was detected in HCT116 
resistant cells in comparison to their sensitive counterpart upon 
cisplatin treatment implying that this is most likely the main 
mechanism of resistance.  In contrast, cisPtI2 is internalised in 
far greater amounts by both cell types with resistant cells even 
showing a slightly greater Pt uptake. 
 However, the correlation between the cytotoxic potency and 
the intracellular Pt content is not straightforward for both 
HCT116 cellular lines. For instance, the Pt content measured 
upon exposure of HCT116-S cells to cisPtI2 is more than two 
times greater compared to exposure to cisplatin. Yet, cisplatin 
produces a greater cytotoxic effect than cisPtI2 (by a factor 2). 
Pairwise, roughly comparable amounts of intracellular Pt are 
found in HCT116-R and HCT116-S cells upon exposure to 
cisPtI2; but cisPtI2 is far more  cytotoxic in the resistant cells 
compared to the sensitive ones (by a factor 3). This implies that 
the nature of the cells and the nature of the Pt complex are still 
important  in determining the overall antiproliferative effect.  
 We believe that the here reported results are very 
meaningful and innovative with respect to current mechanistic 
knowledge on cisplatin and on its analogues for the following 
reasons: 
 
1. In contrast to expectations and to early claims of inactivity 
cisPtI2 is found to produce cytotoxic effects comparable and 
often greater than those caused by cisplatin, at least in four 
representative cancer cell lines; 
2. cisPtI2 overcomes to a large extent resistance to cisplatin in 
a cancer cell line showing acquired resistance to cisplatin, being 
taken up in a far greater amount. This implies that the 
recognition processes for the two Pt complexes are distinct.  
3. However, the large differences measured in Pt uptake 
between cisPtI2 and cisplatin do not correlate with the large 
differences observed in their respective biological effects. The 
nature of the Pt complex and the type of cell still play major 
roles. 
4. The aquation process of cisPtI2 at physiological pH 
reproduces closely that of cisplatin- though being slower-  
involving the progressive release of the two halide ligands; 
however, at slightly acidic pH, cisPtI2 is found to release 
preferentially its ammonia ligands at variance with cisplatin. 
These processes are reproduced very satisfactorily through 
computational analysis of the respective spectral profiles.  t is 
very likely that these differences in reactivity between cisPtI2 
and cisplatin may lead to different interaction modes with 
specific biomolecules, in particular with proteins, thus 
generating distinct pharmacological  profiles.  
5. Remarkably, cisPtI2 produces a kind of DNA damage very 
similar to cisplatin. Yet, the kinetics of Pt binding to DNA is 
slower and the final level of DNA platination appreciably 
lower. As the process of DNA platination is apparently less 
efficient than in the case of cisplatin it is unlikely that DNA is 
the only  or primary target for cisPtI2. when one considers that 
cisPtI2  is even more cytotoxic than cisplatin.  
 Altogether, the reported results delineate an extremely 
favourable biological profile for cisPtI2 and strongly warrant its 
further assessment in appropriate preclinical models. Moreover, 
at least in our opinion, these findings contain relevant 
implications with respect to the postulated mode of action of 
cisplatin and of its analogues. As DNA damage produced by 
cisPtI2 is, on the whole, less extensive and less important than 
that induced by cisplatin and the type of DNA lesion is 
basically the same, the view that the cytotoxic effects of cisPtI2 
may arise from mechanisms other than DNA damage is 
supported. However, more studies are definitely needed to 
further substantiate this hypothesis.  
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